The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The ENCHANT-1 trial (NCT01677455): An open label multicenter phase II proof of concept study evaluating first-line ganetespib monotherapy in women with metastatic HER2-positive or triple-negative breast cancer (TNBC).
Ahmad Awada
No relevant relationships to disclose
Angel Augusto Rodriguez
No relevant relationships to disclose
Anthony Kong
No relevant relationships to disclose
John Kalil Erban
No relevant relationships to disclose
Javier Cortes
Consultant or Advisory Role - Celgene; Novartis; Roche
Honoraria - Celgene; Novartis; Roche
Max S. Mano
No relevant relationships to disclose
Edith A. Perez
No relevant relationships to disclose
Iman El Hariry
Employment or Leadership Position - Synta
Stock Ownership - Synta
Vojislav M. Vukovic
Employment or Leadership Position - Synta
Stock Ownership - Synta
Florentina Teofilovici
Employment or Leadership Position - Synta
Stock Ownership - Synta
Ilker Yalcin
Employment or Leadership Position - Synta
Stock Ownership - Synta
Robert Bradley
Employment or Leadership Position - Synta
Stock Ownership - Synta
David A. Cameron
Consultant or Advisory Role - Synta (U)